“We are proud to partner with Fulgent to launch this innovative, simple, and reliable test that has the potential to redefine the future of cancer testing and foster better patient outcomes.”
Helio health serial#
“We are excited to offer patients at high risk of developing liver cancer a convenient and sensitive serial testing option to catch cancer early when it counts the most,” said Justin Chen Li, U.S. With a specificity of 91%, HelioLiver demonstrated 76% sensitivity in detecting early-stage HCC, significantly outperforming other detection tools such as AFP (57%), GALAD (65%), and ultrasound (47%). Recent data presented at The Liver Meeting® 2021 outlined HelioLiver’s superior sensitivity over currently available blood-based tests. HelioLiver can detect HCC at its earliest stages when lesions are still very small, an area where traditional standard-of-care imaging tools often fall short, with the potential to enable more curative treatment options known to increase five-year survival rates by up to 13 times compared to when cancer has metastasized. (NASDAQ: FLGT) (“Fulgent”), today announced the commercial launch of HelioLiver™, a multi-analyte blood test that incorporates cell free DNA (cfDNA) methylation patterns and serum protein markers for the detection of hepatocellular carcinoma (HCC) – the most common form of liver cancer. IRVINE & TEMPLE CITY, Calif.-( BUSINESS WIRE)- Helio Health (“Helio”) and its commercial partner, Fulgent Genetics, Inc.
0 kommentar(er)
